| MeSH term | MeSH ID | Detail |
|---|---|---|
| Edema | D004487 | 152 associated lipids |
| Precancerous Conditions | D011230 | 48 associated lipids |
| Postoperative Complications | D011183 | 5 associated lipids |
| Arthritis | D001168 | 41 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Surgical Wound Infection | D013530 | 7 associated lipids |
| Neoplasm Recurrence, Local | D009364 | 5 associated lipids |
| Osteonecrosis | D010020 | 5 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Franke EK and Luban J | Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. | 1996 | Virology | pmid:8806510 |
| Spencer DM et al. | Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. | 1996 | Curr. Biol. | pmid:8805308 |
| Zhang Q et al. | Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. | 1996 | Proc. Natl. Acad. Sci. U.S.A. | pmid:8799169 |
| Brunke M et al. | Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases. | 1996 | J. Biol. Chem. | pmid:8798557 |
| Platz KP et al. | Management of acute steroid-resistant rejection after liver transplantation. | 1996 | World J Surg | pmid:8798364 |
| Buckle GJ et al. | HTLV-I-induced T-cell activation. | 1996 | J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. | pmid:8797712 |
| Shapiro R et al. | The superiority of tacrolimus in renal transplant recipients -- the Pittsburgh experience. | 1995 | Clin Transpl | pmid:8794266 |
| Abu-Elmagd K et al. | The current status of hepatic transplantation at the University of Pittsburgh. | 1995 | Clin Transpl | pmid:8794262 |
| Ikebe S et al. | Immunosuppressive effect of tacrolimus (FK-506). Bone xenografts in rabbits. | 1996 | Acta Orthop Scand | pmid:8792745 |
| Venkataramanan R et al. | Clinical pharmacokinetics of tacrolimus. | 1995 | Clin Pharmacokinet | pmid:8787947 |
| Gonschior AK et al. | Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. | 1996 | Clin. Chem. | pmid:8787699 |
| Michel G et al. | Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). | 1996 | Biochem. Pharmacol. | pmid:8787547 |
| Dumont FJ et al. | Mixed agonist/antagonist activity of an FK-506-related immunosuppressant: biological and biochemical characterization. | 1996 | J. Pharmacol. Exp. Ther. | pmid:8786538 |
| Wagenknecht T et al. | Cryoelectron microscopy resolves FK506-binding protein sites on the skeletal muscle ryanodine receptor. | 1996 | Biophys. J. | pmid:8785329 |
| Silva ND and Prendergast FG | Tryptophan dynamics of the FK506 binding protein: time-resolved fluorescence and simulations. | 1996 | Biophys. J. | pmid:8785272 |
| Steiner JP et al. | Immunophilin regulation of neurotransmitter release. | 1996 | Mol. Med. | pmid:8784785 |
| Singh N and Yu VL | Prophylaxis for cytomegalovirus disease after liver transplant. | 1996 | Clin. Infect. Dis. | pmid:8783744 |
| Craescu CT et al. | Three-dimensional structure of the immunophilin-like domain of FKBP59 in solution. | 1996 | Biochemistry | pmid:8780506 |
| Lufft V et al. | Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. | 1996 | Transplantation | pmid:8779695 |
| Newell KA et al. | Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression. | 1996 | Transplantation | pmid:8779685 |
| Schwarz A | [Drug-induced kidney damage]. | 1996 | Z Arztl Fortbild (Jena) | pmid:8779233 |
| Dmitrewski J et al. | Recurrence of primary biliary cirrhosis in the liver allograft: the effect of immunosuppression. | 1996 | J. Hepatol. | pmid:8778189 |
| Mugiya S et al. | Renal blood flow and serotonin metabolism in tacrolimus treated rats. | 1996 | Int. J. Urol. | pmid:8776615 |
| Ichikawa Y et al. | Three-times-daily monotherapy with tacrolimus (FK 506) in kidney transplantation. | 1996 | Int. J. Urol. | pmid:8776613 |
| Randhawa PS et al. | Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. | 1996 | Am. J. Surg. Pathol. | pmid:8772784 |
| Tanaka M et al. | Reduction of immunosuppressive agents after living related donor liver transplantation. | 1996 | Transplant. Proc. | pmid:8769268 |
| Melter M et al. | Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. | 1996 | Transplant. Proc. | pmid:8769224 |
| Baruch Y et al. | Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. | 1996 | Transplant. Proc. | pmid:8769215 |
| Jordan ML et al. | Tacrolimus rescue therapy for renal transplant rejection. | 1996 | Transplant. Proc. | pmid:8769174 |
| Masaki Y et al. | Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. | 1996 | Transplant. Proc. | pmid:8769154 |
| Becker G et al. | Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. | 1996 | Transpl. Immunol. | pmid:8762016 |
| Tomono M et al. | Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts. | 1996 | Biochem. J. | pmid:8760349 |
| Rokaw MD et al. | FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells. | 1996 | Am. J. Physiol. | pmid:8760046 |
| Gusev AI et al. | A quantitative study of in vitro hepatic metabolism of tacrolimus (FK506) using secondary ion and matrix-assisted laser desorption/ionization mass spectrometry. | 1996 | Rapid Commun. Mass Spectrom. | pmid:8759330 |
| Brunner T et al. | Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. | 1996 | Int. Immunol. | pmid:8757947 |
| Venkataraman L et al. | Differential regulation of c-Rel translocation in activated B and T cells. | 1996 | J. Immunol. | pmid:8757620 |
| Sperr WR et al. | Effects of cyclosporin A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. | 1996 | J. Allergy Clin. Immunol. | pmid:8757216 |
| Yamashita M et al. | Non-T cell-derived IL-4 plays an important role in IgE production induced by antigen resensitization and is resistant to FK506. | 1996 | J. Immunol. | pmid:8752921 |
| Motamedi H et al. | Characterization of methyltransferase and hydroxylase genes involved in the biosynthesis of the immunosuppressants FK506 and FK520. | 1996 | J. Bacteriol. | pmid:8752344 |
| Ho SN et al. | Dimeric ligands define a role for transcriptional activation domains in reinitiation. | 1996 | Nature | pmid:8752278 |
| Sunyecz JA et al. | Lymphoproliferative disorder involving the cervix in a patient being treated with FK-506. | 1996 | Gynecol. Oncol. | pmid:8751565 |
| Ichinari H et al. | Effects of portal venous inoculation with donor splenocytes on lung allograft survival in dogs. | 1996 | J. Thorac. Cardiovasc. Surg. | pmid:8751494 |
| Seifeldin R | Drug interactions in transplantation. | 1995 Nov-Dec | Clin Ther | pmid:8750397 |
| Miranker A and Karplus M | An automated method for dynamic ligand design. | 1995 | Proteins | pmid:8749844 |
| Jonas S et al. | Conversion to tacrolimus after liver transplantation. | 1996 | Transpl. Int. | pmid:8748407 |
| Sheppard KE | Cyclosporin A and FK506 are potent activators of proopiomelanocortin-derived peptide secretion without affecting corticotrope glucocorticoid receptor function. | 1995 | J. Neuroendocrinol. | pmid:8748119 |
| Nowaczyk M et al. | 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). | 1995 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:8744655 |
| Cooley HM et al. | Resolution of pyoderma gangrenosum using tacolimus (FK-506) | 1996 | Aust N Z J Med | pmid:8744629 |
| Thompson PA and Mosley CA | Tacrolimus-phenytoin interaction. | 1996 | Ann Pharmacother | pmid:8740340 |
| Ockenfels HM et al. | Inhibition of T cell cAMP formation by cyclosporin A and FK506. | 1996 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:8740144 |